In this issue of The Scientist, we bring you an article by Ricki Lewis on somatic cell nuclear transfer (p. 12) and a Vision by cloning pioneer Ian Wilmut on why research needs cloned human embryonic stem cells (p. 16). On the research front, things are progressing in leaps and bounds. But in other respects the stem cell phenomenon remains, to borrow Winston Churchill's famous observation on Russia, "a riddle wrapped in a mystery inside an enigma."Take the introduction of therapies. It's a riddl
In this issue of
Take the introduction of therapies. It's a riddle. Your horse can be treated today for injuries to tendons, ligaments, and fractures with stem cells,1 but when considering human therapies, no one knows if such approaches will work, and no one knows when we will know. The death of former president Ronald Reagan last year due to Alzheimer's disease had many pundits and even some scientists effusive about the potential for embryonic stem cells ...
When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.
View this Issue
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.
In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.
In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.
Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.
Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST
Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.
Collaboration will bring next generation orchestration and modular automation to scientists worldwide
The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.
